Regulatory Filing
Supriya Lifescience Discloses Judicial Proceedings Against Senior Sales & Marketing Executive
NSE
supriya
BSE
543434
Supriya Lifescience Limited has informed the stock exchanges that judicial proceedings have been initiated against Mr. Sreekant Sreedharan, General Manager – Sales & Marketing, by the Special Investigation and Intelligence Branch of the Customs Department under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The company has clarified that the matter relates to an alleged procedural lapse in a single export transaction and currently expects no material impact on its business operations or financial position.
PRICE-SENSITIVE TRIGGER
Event: Initiation of judicial proceedings against a company personnel.
Type: Regulatory Filing
Impact: Neutral
Immediate Effect: The company has disclosed that judicial proceedings have commenced against one senior employee, while reiterating that there is currently no expected material impact on its operations or governance.
What Happened ?
Supriya Lifescience informed the exchanges that proceedings have been initiated against Mr. Sreekant Sreedharan, General Manager – Sales & Marketing, by the Special Investigation and Intelligence Branch of the Customs Department.
According to the company:
- Proceedings were initiated on 3 July 2026.
- The matter relates to an alleged procedural lapse involving a single export transaction of an identified product.
- The proceedings have been initiated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
- The concerned employee has been granted judicial custody by the CMM Court until July 17, 2026.
The disclosure has been made pursuant to Regulation 30 of the SEBI Listing Regulations.
Key Details
Person Involved:
- Name: Sreekant Sreedharan
- Designation: General Manager – Sales & Marketing
Investigating Authority:
- Special Investigation and Intelligence Branch of the Customs Department.
Nature of Allegation:
- Proceedings relate to an alleged procedural lapse in a single export transaction involving an identified product.
- Action has been initiated under the NDPS Act, 1985.
Company Assessment:
- Based on information currently available:
- No material impact is expected on:
- Operations
- Financial position
- Corporate governance
- No material impact is expected on:
Company Response:
- The company is evaluating the legal implications.
- Appropriate legal advice is being obtained.
- Further action will be taken after examining applicable legal provisions and developments before the competent court.
Compliance:
The disclosure has been made under:
- Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- SEBI Circular dated 13 July 2023 relating to disclosures involving senior management personnel.
Risk Analysis
Summary:
- Although the company currently expects no material business impact, the case involves an employee responsible for sales and marketing and proceedings under the NDPS Act, which could result in reputational and regulatory risks if adverse findings emerge.
Key Risks:
- Ongoing judicial proceedings.
- Potential reputational impact.
- Possibility of additional regulatory scrutiny.
- Legal outcome remains uncertain.
Worst Case:
- If investigations reveal broader compliance failures or company involvement, the matter could lead to regulatory action, reputational damage, or operational disruption. At present, the company has not indicated any such findings.
Risk Level: Medium
Company Commentary
- Proceedings relate to a procedural lapse in a single export transaction.
- Based on current information, no material impact is expected on the company’s operations, financial position, or governance.
- The company is obtaining legal advice and will take appropriate action after evaluating applicable legal provisions and court developments.
- Any further material developments will be disclosed in accordance with applicable regulations.
Official Exchange Filing: Supriya Lifescience Limited
